THE CURE PARKINSON'S TRUST — grant history
Latest income
£15.0m
Grants listed (FY2025)
10
Listed grants total
£8.5m
Accounts grants total
£8.1m
listed grants reconcile with the accounts totalextracted from its FY2025 accounts
What this funder supports
Causes funded
- Education/training
- The Advancement Of Health Or Saving Of Lives
Where grantees operate
- Cardiff
Grants made, per its accounts filings
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| National Institute for Health and Care Research | FY2025 | £5.7m | NIHR - EJS ACT-PD |
| University of Cambridge | FY2025 | £1.1m | DAPA-PD |
| University College London | FY2025 | £464k | Target Trial Emulation; Exenatide; KTP; PD Frontline |
| University of Sheffield | FY2025 | £278k | Repurposing Anti-Gout Medications; PD-CSG; iLCT Screen |
| University of Helsinki | FY2025 | £250k | CDNF and MANF mimetics |
| University of Pittsburgh | FY2025 | £197k | CP-6 nitroalkene in PD |
| University of Buffalo | FY2025 | £194k | Low Dose Lithium |
| University of Coimbra | FY2025 | £174k | GAin-PD |
| German Center for Neurodegenerative Diseases | FY2025 | £152k | Evaluation Of Carnosic Acid |
| Queen Mary, London | FY2025 | £-6k | Type 2 diabetes and PD |
| University College London - ASPro-PD | FY2024 | £5.5m | ASPro-PD |
| Massachuesetts General Hospital (USA) | FY2024 | £247k | Ibuprofen, methylcobalamin, and benfotiamine in a synuclein-based model of LRRK2 and idiopathic Parkinson’s disease |
| Indian Institute of Science Education and Research (India) | FY2024 | £128k | Evaluation of the neuroprotective potential of probucol and chlorogenic acid in a progressive model of Parkinson’s disease |
| University of Coimbra (Portugal) | FY2024 | £76k | GAinPD: Validation of bacterial-derived anti-inflammatory mediators in gut-first PD |
| Garvan Insitute of Medical Research (Australia) | FY2024 | £-680 | Reversal of previous grant/adjustment |
| University of Helsinki (Finland) | FY2024 | £-2k | Reversal of previous grant/adjustment |
| Cardiff University | FY2024 | £-33k | Reversal of previous grant/adjustment |
| University College London - other | FY2024 | £-69k | Reversal of previous grant/adjustment |
| University College London | FY2023 | £275k | PD Frontline: a clinical trial screening and recruitment platform |
| University of Sheffield | FY2023 | £255k | Anti-Gout medications might restore the energy function of cells |
| University Health Network, Toronto | FY2023 | £188k | Might an antibiotic reduce the build-up of alpha-synuclein? |
| Northwestern University | FY2023 | £63k | Preclinical Pharmacokinetics and Efficacy of Intranasal Isradipine |
| University of Edinburgh | FY2023 | £30k | Preclinical investigations of re-purposed and novel compounds that reduce or eliminate synucleinopathy in a human neuronal model of Parkinson’s |
| Queen Mary University, London | FY2023 | £30k | Type 2 diabetes and Parkinson’s disease |
| University of Plymouth | FY2023 | £12k | PD-STAT: simvastatin as a neuroprotective treatment for Parkinson’s disease: a double-blind, randomised, placebo-controlled futility study in patients of moderate severity (PD STAT): A post hoc statistical analysis |
| University of Helsinki (Finland) | FY2021 | £245k | Novel RNA m6A Methyltransferrase activators for Parkinson’s |
| University College London | FY2021 | £223k | PD Frontline 2-year extension |
| Northwestern University Illinois (USA) | FY2021 | £199k | Pre-clinical evaluation of lonafarnib as a treatment for Parkinson’s |
| University College, Cork (Ireland) | FY2021 | £195k | Determining the neuroprotective and neurorestorative efficacy of AAV-hGDF5 |
| University College London | FY2021 | £138k | Dual GLP-1 / GIP receptor agonists for the treatment of Parkinson’s |
| Centre Hospitalier Universitaire de Lille (France) | FY2021 | £96k | Development of a best-in-class iron chelator as a treatment for Parkinson’s |
| University of Sheffield | FY2021 | £79k | Creating a Parkinson’s Clinical Study Group in the UK |
| Queen Mary University, London | FY2021 | £59k | Type 2 diabetes and Parkinson’s (pooled clinical data and biomarker analysis) |
| Cardiff University | FY2021 | £53k | LEARN TransEuro |
| University of Cambridge | FY2021 | £50k | TransEuro Follow-Up Extension |
| University of Plymouth | FY2021 | £20k | Not specified in individual list, but included in Note 4 total |
| University of Edinburgh | FY2021 | £12k | Not specified in individual list, but included in Note 4 total |
| University of Bristol | FY2021 | £10k | Not specified in individual list, but included in Note 4 total |